We are a pharma R&D company dedicated to delivering improved medicines for patients with autoimmune disease, including Multiple Sclerosis.
AZADYNE originated from cutting-edge research from the laboratories of Profs Vincent P. Kelly, Stephen Connon and J. Mike Southern of Trinity Biomedical Sciences Institute, Trinity College Dublin.
Autoimmunity occurs when the body mistakenly attacks itself resulting in inflammation and damage. Over time this can lead to chronic, debilitating diseases such as Multiple Sclerosis, Rheumatoid Arthritis and Inflammatory Bowel Disease. Currently, these diseases are not curable.
Our pioneering approach has identified a naturally occurring micronutrient called queuine with the ability to control autoimmune response in the body. Through novel chemistry and unique insights, AZADYNE has developed new molecules delivering improved therapeutic outcomes for patients and their families. Our candidates are on the path to Phase I or FIH trials.
Founded date: 2016
Investors 4
| Date | Name | Website |
| - | NCL Techno... | ncltv.co.u... |
| 30.09.2022 | 24Haymarke... | 24haymarke... |
| - | NCL Invest... | nclim.co.u... |
| 23.09.2020 | Renaissanc... | rcpinvest.... |
Mentions in press and media 1
| Date | Title | Description | Source |
| 02.04.2019 | New pharma Azadyne raises £1.5m for autoimmune disease treat... | Trinity College’s new spin-out organisation, Azadyne, has completed a £1.5million funding round for ... | nclim.co.u... |